Retraction Note to: Role of RASSF1A promoter methylation in the pathogenesis of hepatocellular carcinoma: a meta-analysis of 21 cohort studies

[1]  Yu-Chen Fan,et al.  Association between Ras association domain family 1A promoter methylation and hepatocellular carcinoma: a meta-analysis. , 2013, World journal of gastroenterology.

[2]  Mengying Liu,et al.  RASSF1A: a potential novel therapeutic target against cardiac hypertrophy. , 2013, Progress in biophysics and molecular biology.

[3]  Zhi-gang Wang,et al.  Quantitative analysis of RASSF1A promoter methylation in hepatocellular carcinoma and its prognostic implications. , 2013, Biochemical and biophysical research communications.

[4]  Jian-guo Li,et al.  Promoter methylation of RASSF1A gene in hepatocellular carcinoma and its clinical significance , 2013 .

[5]  Xiao-mei Zhang,et al.  Effects of DNA methylation and micronucleus formation on pathogenesis of hepatocellular carcinoma by methylation-specific polymerase chain reaction and microscopy , 2013 .

[6]  H. M. Reis,et al.  Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma , 2013, Nature Reviews Cancer.

[7]  Z. Nie,et al.  The Association of RAS Association Domain Family Protein1A (RASSF1A) Methylation States and Bladder Cancer Risk: A Systematic Review and Meta-Analysis , 2012, PloS one.

[8]  Felicia Wu,et al.  Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis. , 2012, European journal of cancer.

[9]  N. Mohamed,et al.  Is serum level of methylated RASSF1A valuable in diagnosing hepatocellular carcinoma in patients with chronic viral hepatitis C? , 2012, Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology.

[10]  S. Bayram.  RASSF1A Ala133Ser polymorphism is associated with increased susceptibility to hepatocellular carcinoma in a Turkish population. , 2012, Gene.

[11]  J. Pe’er,et al.  The role of RASSF1A in uveal melanoma. , 2012, Investigative ophthalmology & visual science.

[12]  H. Taubert,et al.  A RASSF1A polymorphism restricts p53/p73 activation and associates with poor survival and accelerated age of onset of soft tissue sarcoma. , 2012, Cancer research.

[13]  Peng Li,et al.  RASSF1A hypermethylation is associated with aflatoxin B1 and polycyclic aromatic hydrocarbon exposure in hepatocellular carcinoma. , 2011, Hepato-gastroenterology.

[14]  C. Huang,et al.  Clinical significance of methylation of plasma Ras-association domain family 1A gene in the molecular diagnosis of hepatocellular carcinoma , 2011 .

[15]  H. Pan,et al.  Molecular mechanism of liver cancer. , 2011, Anti-cancer agents in medicinal chemistry.

[16]  Jun Wang,et al.  The prognostic value of RASSF1A promoter hypermethylation in non-small cell lung carcinoma: a systematic review and meta-analysis. , 2011, Carcinogenesis.

[17]  Xiaoping Zhou,et al.  Tumor Suppressor RASSF1A Promoter: p53 Binding and Methylation , 2011, PloS one.

[18]  R. Dammann,et al.  Protein kinase A-mediated phosphorylation of the RASSF1A tumour suppressor at Serine 203 and regulation of RASSF1A function. , 2010, European journal of cancer.

[19]  S. Thorgeirsson,et al.  An Integrated Genomic and Epigenomic Approach Predicts Therapeutic Response to Zebularine in Human Liver Cancer , 2010, Science Translational Medicine.

[20]  A. Stang.  Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses , 2010, European Journal of Epidemiology.

[21]  N. Kiviat,et al.  DNA methylation changes in normal liver tissues and hepatocellular carcinoma with different viral infection. , 2010, Experimental and molecular pathology.

[22]  M. Sherman.  Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. , 2010, Seminars in liver disease.

[23]  G. Pfeifer,et al.  The RASSF proteins in cancer; from epigenetic silencing to functional characterization. , 2009, Biochimica et biophysica acta.

[24]  C. la Vecchia,et al.  Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection. , 2009, Cancer letters.

[25]  Yi-jun Wang,et al.  Aberrant DNA methylation profile of hepatocellular carcinoma and surgically resected margin , 2009, Cancer science.

[26]  A. von Deimling,et al.  RASSF1A, BLU, NORE1A, PTEN and MGMT Expression and Promoter Methylation in Gliomas and Glioma Cell Lines and Evidence of Deregulated Expression of de novo DNMTs , 2009, Brain pathology.

[27]  M. Ohira,et al.  The methylation status of RASSF1A promoter predicts responsiveness to chemotherapy and eventual cure in hepatoblastoma patients , 2008, International journal of cancer.

[28]  C. Ding,et al.  Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma. , 2008, Clinical chemistry.

[29]  M. Torbenson,et al.  Epigenetic instability is rare in fibrolamellar carcinomas but common in viral-associated hepatocellular carcinomas , 2008, Modern Pathology.

[30]  W. Tsai,et al.  Predicting Hepatocellular Carcinoma by Detection of Aberrant Promoter Methylation in Serum DNA , 2007, Clinical Cancer Research.

[31]  S. Thorgeirsson,et al.  Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. , 2006, Gastroenterology.

[32]  A. Sutton,et al.  Comparison of two methods to detect publication bias in meta-analysis. , 2006, JAMA.

[33]  John P. A. Ioannidis,et al.  HEGESMA: genome search meta-analysis and heterogeneity testing , 2005, Bioinform..

[34]  A. Tannapfel,et al.  Allele loss and epigenetic inactivation of 3p21.3 in malignant liver tumors , 2005, International journal of cancer.

[35]  W. Yeo,et al.  High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma , 2005, Liver international : official journal of the International Association for the Study of the Liver.

[36]  D. Steinemann,et al.  Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma , 2003, Oncogene.

[37]  Xiaoying Zhang,et al.  Loss of heterozygosity and methylation of multiple tumor suppressor genes on chromosome 3 in hepatocellular carcinoma , 2012, Journal of Gastroenterology.

[38]  Zhang Hao-ye.  Detection of Promoter Hypermethylation of RASSF1A and CDH13 Gene by Nested Methylation Specific Polymerase Chain Reaction in Hepatocellular Carcinoma Patients , 2011 .

[39]  Guo Shen-long.  Methylation status of RASSF1 gene promoter in primary hepatocellular carcinoma and its clinical applications , 2011 .

[40]  Sopit Wongkham,et al.  RASSF1A promoter hypermethylation as a prognostic marker for hepatocellular carcinoma. , 2010, Asian Pacific journal of cancer prevention : APJCP.

[41]  X. Qiu,et al.  Detection of RASSF1A promoter hypermethylation in plasma of patients with primary hepatocellular carcinoma and its clinical significance , 2009 .

[42]  Zhao Qiang.  Diagnostic value of detection of aberrantly methylated RASSF1A in plasma of patients with hepatocellular carcinoma , 2006 .